Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
CEO Jenny Sundqvist gave a very confident impression of why the Conclude phase lll study with Cobitolimod were delayed, how they will speed up the process and what potential triggers to look for in Q4-2023. Further the CEO confirmed earlier estimates for growth in the total addressable UC market.
CDO Dr. Eva Arlander deep dived into the recently announced outcome of the PK-study with Cobitolimod 500 mg dose and how they will use positive data going forward.
Listen to the interview: https://www.inderes.dk/videos/index-pharmaceuticals-update-on-recently-announced-results-of-pk-study-with-cobitolimod
Disclaimer:
HC Andersen Capital receives payment from InDex Pharmaceuticals for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 09:35 AM 03-29-2023.
InDex Pharmaceuticals Holding
InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
Read more on company page